Phase 2 N=12 Pramipexole to Target "Anhedonic Depression"
Depression, Bipolar · Depression, Unipolar · Dysthymia
Primary: Dimensional Anhedonia Rating Scale (DARS) Score — 15.75; 33.08 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=123 Anhedonia, Development, and Emotions: Phenotyping and Therapeutics
Depression · Anhedonia
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) Score — 28.9; 24.9; 21.4; 20.7 score on a scale — p=<0.001
Phase 2 N=93 Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
Anhedonia · Major Depressive Disorder
Primary: Change in Anhedonia Severity, as Measured by Change in DARS Score From Baseline to Day 57 — 17.4; 13.5 units on a scale — p=0.8663
Phase 2 N=55 Targeting Anhedonia in Cocaine Use Disorder
Cocaine-Related Disorders · Anhedonia
Primary: Number of Participants Who Were Cocaine Abstinent as Assessed by Urine Screening (Measure of Treatment Efficacy) — 3; 3; 6 Participants
N/A N=116 Development of a Novel Transdiagnostic Intervention for Anhedonia - R33 Phase
Anhedonia
Primary: Change in Snaith-Hamilton Pleasure Scale Score Over Time — 37.67; 36.96; 29.62; 29.76 score on a scale — p=0.724
N/A N=57 Development of a Novel Transdiagnostic Intervention for Anhedonia - R61 Phase
Anhedonia
Primary: Change From Baseline to Week 15 in Neural Activation — 0.0075; -0.1059 Z-score
N/A N=35 Investigating the Causal Role of Prefrontal Control in Decision-making in Patients With Anhedonia
Major Depressive Disorder · Anhedonia
Primary: Change in the Percentage of Trials That the Participant Chooses to Perform the Hard Task — -0.30; -0.22; -0.09 percentage of trials — p=0.049
Phase 3 N=513 A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
Depressive Disorder, Major · Anhedonia
Primary: Change From Baseline to Day 43 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -11.4; -12.3 Units on a scale — p==0.467
N/A N=100 Translational Model of Anhedonia
Anhedonia
Primary: Reward Positivity Component of the Event-Related Electroencephalogram — 7.29; 9.23 Microvolts — p=.071
Phase 4 N=19 DTA (Dopaminergic Therapy for Anhedonia) Study
Depression · Anhedonia
Primary: Targeted Ventral Striatum to Ventromedial Prefrontal Cortex (VS-vmPFC) Connectivity — 0.183; 0.219; 0.275; 0.202 Mean subject-level FC Z scores
Phase 3 N=444 A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
Depressive Disorder, Major · Anhedonia
Primary: Change From Baseline to Day 43 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -9.4; -10.0 Units on a scale — p==0.670
N/A N=80 Examining Reward-Related Predictors and Mechanisms of Change in BA Treatment for Anhedonic Adolescents
Anhedonia
Primary: Change in Anhedonic (Snaith-Hamilton Pleasure Scale; SHAPS) Symptoms — 7.06; -1.29 units on SHAPS scale
Phase 2 N=23 A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia
Stable Schizophrenia
Primary: Change From Baseline in the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Second Testing After TAK-041 Administration — 29.72; 27.35; 27.89…
Phase 2 N=204 Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
Major Depressive Disorder
Primary: Change From Baseline in Hamilton Depression Rating Scale (HAMD-17) Total Score at Weeks 8 — -9.0; -7.4 Scores on a scale — p=0.121
Early Phase 1 N=13 Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa
Anorexia Nervosa
Primary: Measurement of Brain Activation (Measured in Percent Signal Change) During a Prediction Error Taste Reward Task Using Functional Magnetic Resonance Imaging (fMRI)…
Phase 2 N=89 Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a
ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)
Primary: Change in Ventral Striatal Activation Occurring in Anticipation of Reward During the Monetary Incentive Delay Task Measured by fMRI — 0.718; 0.331 Z score — p=0.0095
N/A N=85 Treatment for Affect Dimensions
Depression · Anxiety
Primary: Positive Affect Subscale of the Positive and Negative Affect Scale (PANAS-P) — 20.76; 29.42; 24.18; 19.42 score on a scale — p=.002
Phase 1 N=93 Differential Responses to Drugs and Sweet Tastes
Bipolar II Disorder
Primary: Change in Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ). — 18.88…
Phase 4 N=10 Brain and Stress Study
Stress, Psychological · Motivation
Primary: Change in Response Bias During the Probabilistic Reward Task — 0.195; 0.203 Ratio (Response Bias Score) — p=0.856
N/A N=18 Study of Mood Effects of Varenicline (Chantix) in Depressed Outpatient Smokers
Depressive Disorder · Smoking
Primary: Change in Quick Inventory of Depressive Symptoms, 16 Question Self-report — 4.7 Units on a scale
Phase 2 N=504 MDD POC Study GSK372475 Subjects Depressive Disease
Depressive Disorder
Primary: Mean Change From Randomization at the End of the Treatment Phase in the MADRS Total Score — -16.9; -19.0; -20.5 Score on scale — p=0.485
Phase 1 N=159 The Effects of Dopamine on Reward Processing
Major Depressive Disorder (MDD)
Primary: Effect on PST Reward Learning — 0.6271; 0.7575; 0.823; 0.7545 Effect size (Beta)